Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Some US Generics May Get To Skip Fed Studies

Requirement May Be Removed If US FDA Research Pans Out

Executive Summary

Office of Generic Drugs official says the FDA may be able to harmonize its requirements with regulators who do not have a blanket mandate.

You may also be interested in...



Generic Industry Market Forces May Impact GDUFA III Talks

AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.

At US Generic Association Annual Meeting, Worries About Sustainability

ANDA sponsors fret price erosion – and potential changes to 180-day exclusivity.

FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On

US agency has received 'very few' inquiries about the drugs on the list since its release.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel